The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Response to comment on "New therapeutic agents in diabetic nephropathy"

  • Kim, Yaeni (Division of Nephrology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea) ;
  • Park, Cheol Whee (Division of Nephrology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea)
  • Received : 2017.04.12
  • Accepted : 2017.04.25
  • Published : 2017.05.01
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Kim Y, Park CW. New therapeutic agents in diabetic nephropathy. Korean J Intern Med 2017;32:11-25. https://doi.org/10.3904/kjim.2016.174
  2. Lindhardt M, Persson F, Currie G, et al. Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial. BMJ Open 2016;6:e010310. https://doi.org/10.1136/bmjopen-2015-010310
  3. Katayama S, Yamada D, Nakayama M, et al. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. J Diabetes Complications 2017;31:758-765. https://doi.org/10.1016/j.jdiacomp.2016.11.021
  4. Sato N, Ajioka M, Yamada T, et al. A randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes and/or chronic kidney disease. Circ J 2016;80:1113-1122. https://doi.org/10.1253/circj.CJ-16-0122
  5. Kolkhof P, Nowack C, Eitner F. Nonsteroidal antagonists of the mineralocorticoid receptor. Curr Opin Nephrol Hypertens 2015;24:417-424. https://doi.org/10.1097/MNH.0000000000000147